“I think they have done a great job”
Lars Kongsbak, CEO in Exiqon, is impressed with the sale of Santaris. It will lead to an increased focus on the LNA technology, he says, and it could benefit his own company.
BY BENJAMIN WERNER CHRISTENSEN
The sale of Santaris to Swiss drug group Roche will not have an immediate impact on the public, Danish gene analysis company, Exiqon, but it could end up having an effect in the long run, CEO Lars Kongsbak tells Medwatch.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Exiqon CEO: Not completely satisfied
For abonnenter
Exiqon CEO: Difficult to find Danish workers
For abonnenter
